Loading organizations...

§ Private Profile · Basel, Switzerland
Nuclidium is a technology company.
Nuclidium develops next-generation copper-based radiopharmaceuticals for precision oncology. Its core technology provides personalized treatment strategies for cancer patients, integrating accurate diagnostics with targeted therapeutic interventions. This approach enables precise disease staging and individualized treatment doses, enhancing efficacy while minimizing systemic impact.
Dr. Leila Jaafar-Thiel founded Nuclidium in 2017, driven by significant unmet needs in cancer care. Her vision stemmed from the insight that a personalized, integrated theranostic approach could improve patient survival and quality of life. The company was established to bridge the diagnostic and therapeutic divide in oncology.
Nuclidium’s offerings target cancer patients seeking advanced, individualized treatment. The company envisions transforming oncology by establishing personalized radiopharmaceutical therapies as the standard of care. This aims to provide effective treatments that improve long-term survival and quality of life for patients.
Nuclidium has raised $100.0M across 1 funding round.
Nuclidium has raised $100.0M in total across 1 funding round.
Nuclidium has raised $100.0M in total across 1 funding round.
Nuclidium's investors include Wellington Partners, Regina Hodits, Daniel Parera, Liliana Nordbakk, Asabys Partners, Bayern Kapital, DeepTech & Climate Fonds, Eurazeo, NRW.BANK, Sandra Schoors.
Nuclidium is a clinical‑stage biotechnology company developing next‑generation copper‑based radiopharmaceuticals (theranostics) for precision oncology, focused on Copper‑61 diagnostics and Copper‑67 therapeutics and building a global production and supply network to make these agents more accessible in hospitals worldwide.[2][5]
High‑Level Overview
For a portfolio/company view:
Origin Story
Core Differentiators
Role in the Broader Tech/Healthcare Landscape
Quick Take & Future Outlook
Quick take: Nuclidium is a well‑funded clinical‑stage radiopharma innovator focused on a copper isotope theranostic platform with momentum in clinical programs and explicit investments in scalable manufacturing—its success will hinge on clinical readouts and the company’s ability to deliver reliable global supply to nuclear medicine centers.[4][2]
Nuclidium has raised $100.0M across 1 funding round. Most recently, it raised $100.0M Series B in July 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jul 1, 2025 | $100M Series B | Wellington Partners, Regina Hodits, Daniel Parera, Liliana Nordbakk | Asabys Partners, Bayern Kapital, DeepTech & Climate Fonds, Eurazeo, NRW.BANK, Sandra Schoors | Announced |